Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $14.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Warren Eric | Officer | Aug 21 '26 | Proposed Sale | $25.98 | 7,437 | $193,188 | — | Aug 21 04:14 PM |
| Rodman David Malcom | Officer | Aug 17 '26 | Proposed Sale | $25.46 | 417 | $10,617 | — | Aug 17 04:38 PM |
| Rodman David Malcom | Officer | Aug 13 '26 | Proposed Sale | $26.48 | 14,056 | $372,187 | — | Aug 13 04:12 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.